Nasdaq
$47.31▼ 1.26%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.77BShares out 79.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
20- 4d agoAfter-hours26.10.21 05:104Ownership#●●●
VERACYTE, INC.
Veracyte, Inc. insider Muna Bhanji filed a Form 4 on October 20, 2026, reporting changes in beneficial ownership of securities as of October 19, 2026. This filing serves as the official disclosure of the insider's equity position adjustment.…more
$47.31-1.26%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.24After-hours26.09.25 05:25144Ownership
VERACYTE, INC.
Veracyte, Inc. insider Jens Holstein has filed an SEC Form 144 to report a proposed sale of company stock. This is a standard filing disclosing an insider's plan to dispose of their holdings.…more
$47.31-1.26%vs prev closeView filingShare - 9.22After-hours26.09.23 06:164Ownership
VERACYTE, INC.
Veracyte executive John Leite reported a change in his beneficial ownership of company securities as of September 21, 2026. This filing serves as an official Form 4 statement regarding the insider's stock holdings.…more
$47.31-1.26%vs prev closeView filingShare
19 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.23 17:00#●●●#●●●
Veracyte Announces Positive Phase III Data for Decipher Prostate Test
Veracyte announced that its Decipher Prostate test successfully predicted treatment benefits in high-risk prostate cancer patients in a Phase III study. These findings strengthen the clinical evidence supporting the use of the test in personalized treatment decision-making.…more
$47.31-1.26%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.16Pre-market26.10.16 22:15
●●●●●●●● ●●●●● ●●●●●●
Veracyte's Prosigna breast cancer recurrence risk test has received Medicare reimbursement coverage. This milestone is expected to facilitate broader adoption and improve patient access to the diagnostic test for early-stage breast cancer.…more
$47.31-1.26%vs prev close - 10.14After-hours26.10.15 05:05
●●●●●●●● ●●●●● ●●●●●●
Veracyte announced it will release its financial results for the third quarter of 2026 after the market closes on November 4, 2026. Management will host a conference call and webcast on the same day to discuss the results and provide a business update.…more
$47.31-1.26%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report